フォローフィードコミュニティでトレーダーや投資家とつながりましょう.
包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.
ターミナル モニターで株式と資産のウォッチリストを整理および監視します
PHILADELPHIA and Vancouver, British Columbia, Dec. 11, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp...
PHILADELPHIA and VANCOUVER, British Columbia, Dec. 11, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp...
Median overall survival (OS) to date of 13.4 months for Phase 2 patients treated with the Phase 3 formulation...
The Data Safety Monitoring Board (DSMB) stated no safety concerns, and recommended continuation of BriaCell’s...
SABCS® “Spotlight” poster to be presented on Wednesday, December 11, 2024 7:00 AM – 8:30 AM CST highlights...
PHILADELPHIA, Pa. and VANCOUVER, British Columbia, Nov. 25, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics...
Phase 1/2 dose escalation study to evaluate BriaCell’s personalized next generation immunotherapy treatment in...
BriaCell’s clinical candidates for next generation breast cancer (Bria-BRES+™) and prostate cancer...
Five BriaCell poster presentations to highlight updated survival and key biomarker data from Phase 2 trial of...
55% of BriaCell patients1 remained alive one year since enrollment in BriaCell’s Phase 2 study, markedly...
35 sites active and enrolling in pivotal Phase 3 study of Bria-IMT™ combination with immune check point...
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 02, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp...
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 01, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp...
Dramatic anti-tumor response includes complete resolution of right temporal lobe brain metastasis in patient...
FDA has authorized the Expanded Access Policy (EAP) to help metastatic breast cancer patients in need for novel...
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約